EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudieOpen Access · CC BY 4.0

Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study

Feng Zhang, Yong-Shuai Wang, Shao-Peng Li, Bin Zhao, Nan Huang, Rui-Peng Song, Fan-Zheng Meng, Zhi-Wen Feng, Shen-Yu Zhang, Hua-Chuan Song, Xiao-Peng Chen iD, Lian-Xin Liu iD und 1 weitere

Journal of Gastroenterology · 2025

DOI: 10.1007/s00535-024-02202-y ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Feng Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, alpha-Fetoproteins, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) are playing a significant role in the treatment of hepatocellular carcinoma (HCC). This study aims to explore the prognostic value of alpha-fetoprotein (AFP) and initial tumor shape irregularity in patients treated with ICIs.

Methods

In this retrospective, multi-center study, 296 HCC patients were randomly divided into the training set and the validation set in a 3:2 ratio. The training set was used to evaluate prognostic factors and to develop an easily applicable ATSI (AFP and Tumor Shape Irregularity) score, which was verified in the validation set.

Results

The ATSI score was developed from two independent prognostic risk factors: baseline AFP ≥ 400 ng/ml (HR 1.73, 95% CI 1.01–2.96, P = 0.046) and initial tumor shape irregularity (HR 1.94, 95% CI 1.03–3.65, P = 0.041). The median overall survival (OS) was not reached (95% CI 28.20–NA) in patients who met no criteria (0 points), 25.8 months (95% CI 14.17–NA) in patients who met one criterion (1 point), and 17.03 months (95% CI 11.73–23.83) in patients who met two criteria (2 points) ( P = 0.001). The median progression-free survival (PFS) was 10.83 months (95% CI 9.27–14.33) for 0 points, 8.03 months (95% CI 6.77–10.57) for 1 point, and 5.03 months (95% CI 3.83–9.67) for 2 points ( P < 0.001). The validation set effectively verified these results (median OS, 37.43/24.27/14.03 months for 0/1/2 points, P = 0.028; median PFS, 13.93/8.30/4.90 months for 0/1/2 points, P < 0.001).

Conclusions

The ATSI score can effectively predict prognosis in HCC patients receiving ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver Neoplasmsalpha-FetoproteinsImmune Checkpoint InhibitorsHumansRetrospective StudiesMaleFemaleMiddle AgedPrognosisAgedAdultPredictive Value of TestsRisk FactorsBiomarkers, Tumor

Stichwörter der Autor:innen

Alpha-fetoproteinHepatocellular carcinomaImmune checkpoint inhibitorPrognosisTumor shape irregularity

Substanzen

alpha-FetoproteinsImmune Checkpoint InhibitorsBiomarkers, TumorAFP protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of C…
  • Anhui Provincial Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui, 230001, China.
  • Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui, 230001, China.
  • Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, 241000, China.
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, Anhui, 241000, China. drcxp@qq.com.

ORCID-Profile: Xiao-Peng Chen, Lian-Xin Liu, Ji-Zhou Wang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, F., Wang, Y. S., Li, S. P., Zhao, B., Huang, N., Song, R. P., Meng, F. Z., Feng, Z. W., Zhang, S. Y., Song, H. C., Chen, X. P., Liu, L. X., & Wang, J. Z. (2025). Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study. Journal of Gastroenterology. https://doi.org/10.1007/s00535-024-02202-y

Vancouver

Zhang F, Wang YS, Li SP, Zhao B, Huang N, Song RP, et al. Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study. Journal of Gastroenterology. 2025. doi:10.1007/s00535-024-02202-y

BibTeX
@article{Zhang2025,
  author = {Zhang, Feng and Wang, Yong-Shuai and Li, Shao-Peng and Zhao, Bin and Huang, Nan and Song, Rui-Peng and Meng, Fan-Zheng and Feng, Zhi-Wen and Zhang, Shen-Yu and Song, Hua-Chuan and Chen, Xiao-Peng and Liu, Lian-Xin and Wang, Ji-Zhou},
  title = {Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study},
  journal = {Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s00535-024-02202-y}
}
Kostenlos starten →